Markets
People interact at the Micron booth at the 3rd China...
People interact at the Micron booth at the Third China International Supply Chain Expo (Sheldon Cooper/Getty Images)

Wall Street analysts love Micron’s earnings. The market already loved them too much ahead of time.

A “sell the news” event.

Micron announced phenomenal fourth-quarter results: a top- and bottom-line beat along with guidance on earnings and profitability for the current quarter that exceeded every Wall Street analyst’s expectations.

And yet the stock is lower, even as the sell side largely sings the memory chip specialist’s praises.

In all, about a dozen analysts hiked their price target on Micron in the wake of these results.

“The company indicated its high bandwidth memory customer base has now increased to six customers and expects to sell out the remainder of its 2026 HBM supply within the next few months,” Needham & Co. analyst N. Quinn Bolton wrote, lifting his price target to $200 from $150 and maintaining a “buy” rating.

Bank of America kept its “neutral” rating on the shares, but lifted its price target to $180 from $140.

“Micron is benefitting from the dual-drivers of surging AI demand (driver of high bandwidth memory or HBM sales) and the memory industry’s (abnormal) supply discipline that has pushed up pricing in traditional (D4) and new (D5) markets,” analyst Vivek Arya wrote.

The problem seems to be that Wall Street has been in catch-up mode on the company, leading to a bit of a “sell the news” event.

On August 11, Micron told investors that the results it just reported would be better than management previously expected. And in September, the stock went on an absolute tear, with a record 12-session winning streak that pushed the price above the average target from the sell side. That move occurred amid a bevy of positive news on the persistence of the AI build-out, headlined by purchase commitments from OpenAI that range from $10 billion (with Broadcom) to the hundreds of billions (with Oracle). Micron’s memory chips are slated to play a supporting role in this continued aggressive development of AI infrastructure.

It’s much easier to say with hindsight that these fantastic results and outlook were priced in. But even a cursory look at the above chart would suggest that Micron needed to be an Olympic-level hurdler to clear the bar the market had set for this quarter.

“We made the case in our preview that even with excellent near term conditions, that the stock is nearing peak valuation if we treat them the way that we would historically treat a memory business,” wrote Morgan Stanley’s Joseph Moore, who kept his “neutral” rating and $160 price target intact following these results. “The stock is expensive on book value, extremely expensive on FCF metrics (which is our primary rationale for buying a memory stock), and is inexpensive on near term earnings, but expensive on cycle adjusted earnings.”

Even with today’s drop, shares of Micron are still up more than 30% this month.

More Markets

See all Markets
markets

Momentum stocks sputter, weighing on markets

Risky momentum stocks that retail traders piled into this year sputtered on Wednesday, throwing a bit of sand in the market rally.

Recent retail favorites like Rocket Lab, Hims & Hers, Palantir, Oklo, and SoundHound AI — all members of Goldman Sachs’ thematic basket of “high beta momentum stocks” — were in the red on the day, with little specific company news, suggesting the pullback is more about the market rethinking a broad-based trade rather than expressing specific concerns about individual companies.

Shortly before 1 p.m. ET, the iShares MSCI USA Momentum Factor ETF was down 0.7%, its worst day since late August.

Why is momentum suddenly sputtering? That’s the tricky bit.

The current crop of momentum stocks tends to be stocks with very high valuation ratios, suggesting that the traders buying them are betting their earnings will come far in the future rather than any time soon. (That is, of course, if they’re not just buying them based on the fact that they’ve gone up a lot.) But it’s impossible to say exactly why the momentum trade is fizzling a bit today.

It could be that after a giant romp — Rocket Lab, for example, is up almost 50% over the last three months — these stocks just need a breather.

markets

Canopy rallies after CEO stock purchase

Canopy Growth rallied on Wednesday after its CEO, Luc Mongeau, disclosed an unplanned stock purchase on Tuesday.

Mongeau, who joined Canopy from Mars in January, bought 27,469 shares at CA$1.84. The buy is worth about US$36,259.

It has been a tumultuous time for cannabis stocks, as the market in Canada (where Canopy is located) stagnates and cannabis reform in the US has yet to move forward.

markets

Robinhood, new S&P 500 leader, the subject of favorable analyst chatter

Robinhood Markets briefly touched a new all-time intraday high in early trading after the newly minted — and now top-performing — member of the the S&P 500 received some favorable write-ups from Wall Street analysts.

(Robinhood Markets Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions. I own stock as part of my compensation.)

Piper Sandler analysts highlighted momentum in the company’s prediction markets business thanks to the rollout of contracts on college and profession football, noting that the event contracts business was running at a $200 million annualized rate so far in September. They raised their price target on the shares to $140 from $120.

“Prediction Markets (aka event contracts) present significant upside opportunity for Robinhood,” Piper Sandler’s Patrick Moley wrote.

Elsewhere, Citi analysts raised their Q3 and full-year 2025 estimates and upped their price target on the shares to $135, but kept a “neutral” rating on the stock.

“While HOOD continues to see solid momentum across the platform, we believe the stock is pricing in much of the growth potential in our view. Given current valuations and where we are in the retail cycle (closer to the highs than the lows from an activity perspective from our viewpoint), we prefer to wait for a more reasonable entry point at present.”

The stock has clearly had a heck of a run.

Through yesterday’s close, Robinhood was up nearly 240% in 2025. Since it was added to the S&P 500 on Monday, it’s now the top performer among the blue chips, trouncing previous leaders Seagate Technology Holdings and Palantir.

markets

UniQure surges after encouraging trial results for Huntington’s treatment

UniQure rose more than 150% in early trading Wednesday after it released trial results that showed its experimental gene therapy for Huntington’s disease slowed its progression by 75% after three years.

The treatment, AMT-130, is a one-time treatment for Huntington’s, a genetic brain disease that degrades cognitive function and muscle control. There is currently no cure for the disease.

UniQure said it plans to submit the treatment for approval to the Food and Drug Administration in the first quarter of 2026, meaning it could become available to patients later that year. The company currently makes nearly all of its revenue from gene therapies that treat hemophilia.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.